{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:31:16Z","timestamp":1781796676672,"version":"3.54.5"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11899-025-00764-z","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:26:54Z","timestamp":1762507614000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Transforming the Treatment of Acute Lymphoblastic Leukemia: the Role of Bispecific Antibodies, Antibody-Drug Conjugates, and CAR T-cell Therapy"],"prefix":"10.1007","volume":"20","author":[{"given":"Tala","family":"Najdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Khanfour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Chalhoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shereen","family":"Sakkal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi G.","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hampig Raphael","family":"Kourie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"issue":"7","key":"764_CR1","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O","volume":"86","author":"DA Thomas","year":"1999","unstructured":"Thomas DA, Kantarjian H, Smith TL, Koller C, Cortes J, O\u2019Brien S, et al. Primary refractory and relapsed adult acute lymphoblastic leukemia. Cancer. 1999;86(7):1216\u201330.","journal-title":"Cancer"},{"issue":"10","key":"764_CR2","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","volume":"120","author":"N G\u00f6kbuget","year":"2012","unstructured":"G\u00f6kbuget N, Stanze D, Beck J, Diedrich H, Horst HA, H\u00fcttmann A, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120(10):2032\u201341.","journal-title":"Blood."},{"key":"764_CR3","unstructured":"Defining the course. and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration - PubMed [Internet]. [cited 2025 Mar 2]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/20737576\/"},{"issue":"26","key":"764_CR4","doi-asserted-by":"publisher","first-page":"5094","DOI":"10.1182\/blood-2012-10-460394","volume":"120","author":"R Bassan","year":"2012","unstructured":"Bassan R. Toward victory in adult ALL: blinatumomab joins in. Blood. 2012;120(26):5094\u20135.","journal-title":"Blood"},{"issue":"9","key":"764_CR5","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, Fielding AK, Schuh AC, Ribera JM, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836\u201347.","journal-title":"N Engl J Med"},{"issue":"8","key":"764_CR6","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740\u201353.","journal-title":"N Engl J Med"},{"key":"764_CR7","unstructured":"Research C, for DE. and. FDA approves inotuzumab ozogamicin for pediatric patients with acute lymphoblastic leukemia. FDA [Internet]. 2024 Mar 6 [cited 2025 Mar 9]; Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-inotuzumab-ozogamicin-pediatric-patients-acute-lymphoblastic-leukemia"},{"issue":"9","key":"764_CR8","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1200\/JCO.22.00642","volume":"41","author":"TW Laetsch","year":"2023","unstructured":"Laetsch TW, Maude SL, Rives S, Hiramatsu H, Bittencourt H, Bader P, et al. Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial. J Clin Oncol. 2023;41(9):1664\u20139.","journal-title":"J Clin Oncol"},{"issue":"5","key":"764_CR9","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/s41375-025-02532-7","volume":"39","author":"BD Shah","year":"2025","unstructured":"Shah BD, Cassaday RD, Park JH, Houot R, Logan AC, Boissel N, et al. Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. Leukemia. 2025;39(5):1058\u201368.","journal-title":"Leukemia"},{"key":"764_CR10","unstructured":"ALL Hub. ZUMA-3 trial: 3-year follow-up analysis. Available from: https:\/\/lymphoblastic-hub.com\/medical-information\/zuma-3-trial-3-year-follow-up-analysis. [cited 2025 Aug 15]."},{"key":"764_CR11","unstructured":"Research C. for DE and. FDA approves brexucabtagene autoleucel for relapsed or refractory B-cell precursor acute lymphoblastic leukemia. FDA [Internet]. 2024 Aug 9 [cited 2025 Mar 1]; Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic"},{"issue":"23","key":"764_CR12","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","volume":"391","author":"C Roddie","year":"2024","unstructured":"Roddie C, Sandhu KS, Tholouli E, Logan AC, Shaughnessy P, Barba P, et al. Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia. N Engl J Med. 2024;391(23):2219\u201330.","journal-title":"N Engl J Med"},{"key":"764_CR13","unstructured":"Research C. for DE and. FDA approves obecabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. FDA [Internet]. 2024 Nov 8 [cited 2025 Aug 15]; Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-obecabtagene-autoleucel-adults-relapsed-or-refractory-b-cell-precursor-acute"},{"issue":"2","key":"764_CR14","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.ymthe.2020.09.027","volume":"29","author":"V Ort\u00edz-Maldonado","year":"2021","unstructured":"Ort\u00edz-Maldonado V, Rives S, Castell\u00e0 M, Alonso-Saladrigues A, Ben\u00edtez-Ribas D, Caballero-Ba\u00f1os M, et al. CART19-BE-01: a multicenter trial of ARI-0001 cell therapy in patients with CD19\u2009+\u2009relapsed\/refractory malignancies. Mol Ther. 2021;29(2):636\u201344.","journal-title":"Mol Ther"},{"issue":"5","key":"764_CR15","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Rivi\u00e8re I, Gonen M, Wang X, S\u00e9n\u00e9chal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449\u201359.","journal-title":"N Engl J Med"},{"issue":"3","key":"764_CR16","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/bjh.15195","volume":"181","author":"S Li","year":"2018","unstructured":"Li S, Zhang J, Wang M, Fu G, Li Y, Pei L, et al. Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB. Br J Haematol. 2018;181(3):360\u201371.","journal-title":"Br J Haematol"},{"issue":"1","key":"764_CR17","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13045-020-00953-8","volume":"13","author":"R Gu","year":"2020","unstructured":"Gu R, Liu F, Zou D, Xu Y, Lu Y, Liu B, et al. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia. J Hematol Oncol. 2020;13(1):122.","journal-title":"J Hematol Oncol."},{"issue":"10","key":"764_CR18","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1002\/ajh.25582","volume":"94","author":"H Jiang","year":"2019","unstructured":"Jiang H, Li C, Yin P, Guo T, Liu L, Xia L, et al. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed\/refractory B-cell acute lymphoblastic leukemia: an open-label pragmatic clinical trial. Am J Hematol. 2019;94(10):1113\u201322.","journal-title":"Am J Hematol"},{"issue":"2","key":"764_CR19","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/bjh.16623","volume":"191","author":"J Wang","year":"2020","unstructured":"Wang J, Mou N, Yang Z, Li Q, Jiang Y, Meng J, et al. Efficacy and safety of humanized anti-CD19-CAR-T therapy following intensive lymphodepleting chemotherapy for refractory\/relapsed B acute lymphoblastic leukaemia. Br J Haematol. 2020;191(2):212\u201322.","journal-title":"Br J Haematol"},{"issue":"4","key":"764_CR20","volume":"20","author":"Y Ma","year":"2020","unstructured":"Ma Y, Zhang S, Fang H, Yu K, Jiang S. A phase I study of CAR-T bridging HSCT in patients with acute CD19\u2009+\u2009relapse\/refractory B-cell leukemia. Oncol Lett. 2020;20(4):20.","journal-title":"Oncol Lett"},{"issue":"4","key":"764_CR21","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa2312948","volume":"391","author":"MR Litzow","year":"2024","unstructured":"Litzow MR, Sun Z, Mattison RJ, Paietta EM, Roberts KG, Zhang Y, et al. Blinatumomab for MRD-Negative acute lymphoblastic leukemia in adults. N Engl J Med. 2024;391(4):320\u201333.","journal-title":"N Engl J Med."},{"issue":"Supplement 1","key":"764_CR22","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1182\/blood-2021-146163","volume":"138","author":"N Boissel","year":"2021","unstructured":"Boissel N, Huguet F, Graux C, Hicheri Y, Chevallier P, Kim R, et al. Frontline consolidation with blinatumomab for high-risk Philadelphia-negative acute lymphoblastic adult patients. Early results from the Graall-2014-QUEST phase 2. Blood. 2021;138(Supplement 1):1232\u20131232.","journal-title":"Blood"},{"key":"764_CR23","doi-asserted-by":"crossref","unstructured":"Bassan R, Chiaretti S, Della Starza I, Santoro A, Spinelli O, Tosi M et al. Up-front blinatumomab improves mrd clearance and outcome in adult ph-b-lineage all: the GIMEMA LAL2317 phase 2 study. Blood. (2025);2024027500.","DOI":"10.1182\/blood.2024027500"},{"issue":"12","key":"764_CR24","doi-asserted-by":"publisher","first-page":"e878","DOI":"10.1016\/S2352-3026(22)00285-X","volume":"9","author":"E Jabbour","year":"2022","unstructured":"Jabbour E, Short NJ, Jain N, Thompson PA, Kadia TM, Ferrajoli A, et al. Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 2022;9(12):e878\u201385.","journal-title":"Lancet Haematol"},{"issue":"3","key":"764_CR25","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1002\/ajh.27576","volume":"100","author":"H Kantarjian","year":"2025","unstructured":"Kantarjian H, Short NJ, Jain N, Haddad FG, Kadia T, Yilmaz M, et al. Hyper-CVAD and sequential blinatumomab without and with inotuzumab in young adults with newly diagnosed Philadelphia Chromosome-negative B-cell acute lymphoblastic leukemia. Am J Hematol. 2025;100(3):402\u20137.","journal-title":"Am J Hematol"},{"issue":"Suppl","key":"764_CR26","doi-asserted-by":"publisher","first-page":"e811479d","DOI":"10.1097\/01.HS9.0000968372.81147.9d","volume":"7","author":"S Fleming","year":"2023","unstructured":"Fleming S, Reynolds J, Bajel A, Venn N, Kwan J, Moore J, et al. P365: SEQUENTIAL BLINATUMOMAB WITH REDUCED INTENSITY CHEMOTHERAPY FOR OLDER ADULTS WITH NEWLY DIAGNOSED PH- B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA \u2013 FINAL RESULTS OF THE ALLG ALL08 STUDY. Hemasphere. 2023;7(Suppl):e811479d.","journal-title":"Hemasphere"},{"issue":"Supplement 1","key":"764_CR27","doi-asserted-by":"publisher","first-page":"3258","DOI":"10.1182\/blood-2022-157361","volume":"140","author":"C Salek","year":"2022","unstructured":"Salek C, Folber F, Hrabovsky S, Koristek Z, Horacek JM, Fronkova E, et al. Single cycle of blinatumomab followed by high-dose chemotherapy in the induction therapy for Ph-negative acute lymphoblastic leukemia in adults. Primary endpoint analysis of the Blina-Cell trial. Blood. 2022;140(Supplement 1):3258\u20139.","journal-title":"Blood"},{"issue":"Supplement 1","key":"764_CR28","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1182\/blood-2023-180472","volume":"142","author":"N Goekbuget","year":"2023","unstructured":"Goekbuget N, Schwartz S, Faul C, Topp MS, Subklewe M, Renzelmann A, et al. Dose reduced chemotherapy in sequence with blinatumomab for newly diagnosed older patients with Ph\/BCR::ABL negative B-Precursor adult lymphoblastic leukemia (ALL): preliminary results of the GMALL bold trial. Blood. 2023;142(Supplement 1):964.","journal-title":"Blood"},{"issue":"14","key":"764_CR29","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1200\/JCO.21.01766","volume":"40","author":"AS Advani","year":"2022","unstructured":"Advani AS, Moseley A, O\u2019Dwyer KM, Wood BL, Fang M, Wieduwilt MJ, et al. SWOG 1318: A phase II trial of blinatumomab followed by POMP maintenance in older patients with newly diagnosed Philadelphia Chromosome-Negative B-Cell acute lymphoblastic leukemia. J Clin Oncol. 2022;40(14):1574\u201382.","journal-title":"J Clin Oncol"},{"issue":"11","key":"764_CR30","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1002\/ajh.27463","volume":"99","author":"WY Jen","year":"2024","unstructured":"Jen WY, Jabbour E, Short NJ, Issa GC, Haddad FG, Jain N, et al. A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia. Am J Hematol. 2024;99(11):2229\u201332.","journal-title":"Am J Hematol"},{"issue":"17","key":"764_CR31","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","volume":"383","author":"R Fo\u00e0","year":"2020","unstructured":"Fo\u00e0 R, Bassan R, Vitale A, Elia L, Piciocchi A, Puzzolo MC, et al. Dasatinib-Blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N Engl J Med. 2020;383(17):1613\u201323.","journal-title":"N Engl J Med"},{"issue":"7","key":"764_CR32","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1182\/bloodadvances.2022008216","volume":"7","author":"AS Advani","year":"2023","unstructured":"Advani AS, Moseley A, O\u2019Dwyer KM, Wood BL, Park J, Wieduwilt M, et al. Dasatinib\/prednisone induction followed by blinatumomab\/dasatinib in Ph\u2009+\u2009acute lymphoblastic leukemia. Blood Adv. 2023;7(7):1279\u201385.","journal-title":"Blood Adv"},{"issue":"36","key":"764_CR33","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.1200\/JCO.24.00272","volume":"42","author":"H Kantarjian","year":"2024","unstructured":"Kantarjian H, Short NJ, Haddad FG, Jain N, Huang X, Montalban-Bravo G, et al. Results of the simultaneous combination of Ponatinib and blinatumomab in Philadelphia chromosome-positive ALL. J Clin Oncol. 2024;42(36):4246\u201351.","journal-title":"J Clin Oncol"},{"issue":"1","key":"764_CR34","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","volume":"10","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, et al. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol. 2023;10(1):e24\u201334.","journal-title":"Lancet Haematol"},{"key":"764_CR35","doi-asserted-by":"crossref","unstructured":"Chiaretti S. Comparison between dasatinib-blinatumomab vs ponatinib-blinatumomab chemo-free strategy for newly diagnosed ph\u2009+\u2009acute lymphoblastic leukemia patients. Preliminary Results of the Gimema ALLL2820 Trial. In ASH; 2023 [cited 2025 Aug 15]. Available from: https:\/\/ash.confex.com\/ash\/2023\/webprogram\/Paper189632.html","DOI":"10.1182\/blood-2023-189632"},{"issue":"Supplement 1","key":"764_CR36","doi-asserted-by":"publisher","first-page":"6114","DOI":"10.1182\/blood-2022-166035","volume":"140","author":"P Chevallier","year":"2022","unstructured":"Chevallier P, Leguay T, Kim R, Delord M, Doubek M, Huguet F, et al. Fractionated inotuzumab ozogamicin combined with low-intensity chemotherapy in older patients with newly diagnosed CD22\u2009+\u2009Philadelphia chromosome (Ph)-negative B-cell precursor (BCP) acute lymphoblastic leukemia (ALL): results of the EWALL-INO study. Blood. 2022;140(Supplement 1):6114\u20136.","journal-title":"Blood"},{"issue":"3","key":"764_CR37","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1200\/JCO.23.00546","volume":"42","author":"M Stelljes","year":"2024","unstructured":"Stelljes M, Raffel S, Alakel N, W\u00e4sch R, Kondakci M, Scholl S, et al. Inotuzumab ozogamicin as induction therapy for patients older than 55 years with Philadelphia Chromosome-Negative B-precursor ALL. J Clin Oncol. 2024;42(3):273\u201382.","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"764_CR38","doi-asserted-by":"publisher","first-page":"7006","DOI":"10.1200\/JCO.2023.41.16_suppl.7006","volume":"41","author":"MJ Wieduwilt","year":"2023","unstructured":"Wieduwilt MJ, Yin J, Kour O, Teske R, Stock W, Byrd K, et al. Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703. JCO. 2023;41(16_suppl):7006\u20137006.","journal-title":"JCO"},{"key":"764_CR39","doi-asserted-by":"crossref","unstructured":"Jabbour E, Short NJ, Senapati J, Jain N, Huang X, Daver N, et al. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol. (2023);10(6):e433\u201344.","DOI":"10.1016\/S2352-3026(23)00073-X"},{"issue":"4","key":"764_CR40","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1016\/j.clml.2023.12.016","volume":"24","author":"NJ Short","year":"2024","unstructured":"Short NJ, Jabbour E, Jamison T, Paul S, Cuglievan B, McCall D, et al. Dose-Dense Mini-Hyper-CVD, inotuzumab Ozogamicin and blinatumomab achieves rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2024;24(4):e168\u201373.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"764_CR41","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2021.0987","volume":"325","author":"F Locatelli","year":"2021","unstructured":"Locatelli F, Zugmaier G, Rizzari C, Morris JD, Gruhn B, Klingebiel T, et al. Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325(9):843\u201354.","journal-title":"JAMA"},{"issue":"Supplement 1","key":"764_CR42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-188118","volume":"142","author":"M Schwartz","year":"2023","unstructured":"Schwartz M, McMahon CM, Amaya ML, Witkowski M, Pollyea DA, Gutman JA, et al. Consolidation with Ponatinib plus sequential blinatumomab and chemotherapy after low intensity Dasatinib-based induction in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: outcomes from a single institution. Blood. 2023;142(Supplement 1):4247.","journal-title":"Blood"},{"issue":"Suppl 16","key":"764_CR43","doi-asserted-by":"publisher","first-page":"10016","DOI":"10.1200\/JCO.2023.41.16_suppl.10016","volume":"41","author":"MM O\u2019Brien","year":"2023","unstructured":"O\u2019Brien MM, McNeer JL, Rheingold SR, Devidas M, Chen Z, Bhojwani D, et al. A phase 3 trial of inotuzumab ozogamicin for high-risk B-ALL: Second safety phase results from Children\u2019s Oncology Group AALL1732. J Clin Oncol. 2023;41(Suppl 16):10016\u201310016.","journal-title":"J Clin Oncol."},{"issue":"6","key":"764_CR44","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1182\/bloodadvances.2023011514","volume":"8","author":"LL Metheny","year":"2024","unstructured":"Metheny LL, Sobecks R, Cho C, Fu P, Margevicius S, Wang J, et al. A multicenter study of posttransplantation low-dose inotuzumab Ozogamicin to prevent relapse of acute lymphoblastic leukemia. Blood Adv. 2024;8(6):1384\u201391.","journal-title":"Blood Adv"},{"key":"764_CR45","doi-asserted-by":"crossref","unstructured":"Jabbour E, Richard-Carpentier G, Sasaki Y, Konopleva M, Patel K, Roberts K, et al. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol. (2020);7(7):e523\u201333.","DOI":"10.1016\/S2352-3026(20)30144-7"},{"issue":"23","key":"764_CR46","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.1002\/cncr.29646","volume":"121","author":"F Ravandi","year":"2015","unstructured":"Ravandi F, O\u2019Brien SM, Cortes JE, Thomas DM, Garris R, Faderl S, et al. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015;121(23):4158\u201364.","journal-title":"Cancer"},{"issue":"12","key":"764_CR47","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1182\/blood-2009-12-261586","volume":"116","author":"F Ravandi","year":"2010","unstructured":"Ravandi F, O\u2019Brien S, Thomas D, Faderl S, Jones D, Garris R, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood. 2010;116(12):2070\u20137.","journal-title":"Blood"},{"issue":"8","key":"764_CR48","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1200\/JCO.23.01075","volume":"42","author":"R Fo\u00e0","year":"2024","unstructured":"Fo\u00e0 R, Bassan R, Elia L, Piciocchi A, Soddu S, Messina M, et al. Long-term results of the Dasatinib-Blinatumomab protocol for adult Philadelphia-positive ALL. J Clin Oncol. 2024;42(8):881\u20135.","journal-title":"J Clin Oncol"},{"issue":"12","key":"764_CR49","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.clml.2017.08.101","volume":"17","author":"R Assi","year":"2017","unstructured":"Assi R, Kantarjian H, Short NJ, Daver N, Takahashi K, Garcia-Manero G, et al. Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia Chromosome-positive leukemia. Clin Lymphoma Myeloma Leuk. 2017;17(12):897\u2013901.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"21","key":"764_CR50","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1001\/jama.2024.4783","volume":"331","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Kantarjian HM, Aldoss I, Montesinos P, Leonard JT, G\u00f3mez-Almaguer D, et al. Ponatinib vs Imatinib in Frontline Philadelphia Chromosome\u2013Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA. 2024;331(21):1814\u201323.","journal-title":"JAMA"},{"key":"764_CR51","unstructured":"University of Chicago. A Phase ii study of a chemotherapy-free induction regimen for ph\u2009+\u2009acute lymphoblastic leukemia (ALL) incorporating inotuzumab ozogamicin (ino) [internet]. clinicaltrials.gov; 2025 Mar [cited 2025 Oct 2]. Report No.: NCT04747912. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04747912"},{"issue":"21","key":"764_CR52","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1182\/blood.V124.21.379.379","volume":"124","author":"N Goekbuget","year":"2014","unstructured":"Goekbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Havelange V, et al. BLAST: a confirmatory, single-arm, phase 2 study of blinatumomab, a bispecific T-cell engager (BiTE\u00ae) antibody construct, in patients with minimal residual disease B-precursor acute lymphoblastic leukemia (ALL). Blood. 2014;124(21):379.","journal-title":"Blood"},{"issue":"36","key":"764_CR53","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","volume":"32","author":"MS Topp","year":"2014","unstructured":"Topp MS, G\u00f6kbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32(36):4134\u201340.","journal-title":"J Clin Oncol"},{"key":"764_CR54","first-page":"266","volume":"6","author":"A Rijneveld","year":"2022","unstructured":"Rijneveld A, Gradowska P, Bellido M, de Weerdt O, Gadisseur A, Deeren D, et al. P366: blinatumomab added to prephase and consolidation therapy in newly diagnosed precursor B-ALL in adults. A phase II hovon trial HemaSphere. 2022;6:266.","journal-title":"A phase II hovon trial. HemaSphere."},{"key":"764_CR55","doi-asserted-by":"crossref","unstructured":"Cabannes-Hamy A, Brissot E, Leguay T, Huguet F, Chevallier P, Hunault M et al. High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL. Haematologica. (2022)1;107(9):2072\u201380.","DOI":"10.3324\/haematol.2021.280078"},{"issue":"9","key":"764_CR56","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1002\/ajh.26634","volume":"97","author":"EJ Jabbour","year":"2022","unstructured":"Jabbour EJ, Short NJ, Jain N, Jammal N, Jorgensen J, Wang S, et al. Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10-4 and higher. Am J Hematol. 2022;97(9):1135\u201341.","journal-title":"Am J Hematol"},{"key":"764_CR57","unstructured":"Blinatumomab for minimal. Residual disease in adults with B-cell precursor acute lymphoblastic leukemia - PubMed [Internet]. [cited 2025 Mar 8]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29358182\/"},{"issue":"5","key":"764_CR58","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1182\/blood.2023022330","volume":"143","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Haddad FG, Short NJ, Senapati J, Jain N, Sasaki K, et al. Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission. Blood. 2024;143(5):417\u201321.","journal-title":"Blood"},{"issue":"Supplement 1","key":"764_CR59","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-209438","volume":"144","author":"DJ DeAngelo","year":"2024","unstructured":"DeAngelo DJ, Yin J, Advani AS, Luger S, Fulcher J, Liedtke M, et al. Addition of inotuzumab to a pediatric inspired chemotherapy regimen in young adult patients with B-cell acute lymphoblastic leukemia: findings from the alliance A041501 phase 3 randomized trial. Blood. 2024;144(Supplement 1):308.","journal-title":"Blood"},{"issue":"18","key":"764_CR60","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","volume":"20","author":"MS Topp","year":"2011","unstructured":"Topp MS, Kufer P, G\u00f6kbuget N, Goebeler M, Klinger M, Neumann S, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29(18):2493\u20138.","journal-title":"J Clin Oncol."},{"issue":"21","key":"764_CR61","doi-asserted-by":"publisher","first-page":"3703","DOI":"10.1182\/blood.V124.21.3703.3703","volume":"124","author":"L Gore","year":"2014","unstructured":"Gore L, Locatelli F, Zugmaier G, Zwaan CM, Bhojwani D, Handgretinger R, et al. Initial results from a phase 2 study of blinatumomab in pediatric patients with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia. Blood. 2014;124(21):3703.","journal-title":"Blood"},{"issue":"21","key":"764_CR62","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1182\/blood.V124.21.2292.2292","volume":"124","author":"A von Stackelberg","year":"2014","unstructured":"von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C. Phase 1\/2 study in pediatric patients with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL) receiving Blinatumomab treatment. Blood. 2014;124(21):2292.","journal-title":"Blood"},{"issue":"1","key":"764_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00766-7","volume":"13","author":"N Boissel","year":"2023","unstructured":"Boissel N, Chiaretti S, Papayannidis C, Ribera JM, Bassan R, Sokolov AN, et al. Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study. Blood Cancer J. 2023;13(1):2.","journal-title":"Blood Cancer J"},{"key":"764_CR64","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41408-022-00606-8","volume":"12","author":"K Hein","year":"2022","unstructured":"Hein K, Short N, Jabbour E, Yilmaz M. Clinical value of measurable residual disease in acute lymphoblastic leukemia. Blood Lymphat Cancer. 2022;12:7\u201316.","journal-title":"Blood Lymphat Cancer"},{"key":"764_CR65","unstructured":"Long-term response. to autologous anti-CD19 chimeric antigen receptor T cells in relapsed or refractory B cell acute lymphoblastic leukemia: a systematic review and meta-analysis | Cancer Gene Therapy [Internet]. [cited 2025 Mar 2]. Available from: https:\/\/www.nature.com\/articles\/s41417-023-00593-3"},{"key":"764_CR66","doi-asserted-by":"crossref","unstructured":"Stefanski HE, Verneris MR, Eaton A, Baggott C, Prabhu S, Pacenta HL et al. Post-relapse outcomes following tisagenlecleucel: poor survival, despite current salvage therapies: results from the pediatric real world car consortium (PRWCC). In Tandem Meetings; 2021 [cited 2025 Mar 2]. Available from: https:\/\/tct.confex.com\/tandem\/2021\/meetingapp.cgi\/Paper\/17184","DOI":"10.1016\/S2666-6367(21)00152-4"},{"issue":"9","key":"764_CR67","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1182\/bloodadvances.2024012885","volume":"8","author":"RM Myers","year":"2024","unstructured":"Myers RM, Devine K, Li Y, Lawrence S, Leahy AB, Liu H, et al. Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia. Blood Adv. 2024;8(9):2182\u201392.","journal-title":"Blood Adv"},{"issue":"23","key":"764_CR68","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1182\/blood.V126.23.683.683","volume":"126","author":"SL Maude","year":"2015","unstructured":"Maude SL, Barrett DM, Ambrose DE, Rheingold SR, Aplenc R, Teachey DT, et al. Efficacy and safety of humanized chimeric antigen receptor (CAR)-modified T cells targeting CD19 in children with relapsed\/refractory ALL. Blood. 2015;126(23):683.","journal-title":"Blood"},{"issue":"Supplement 1","key":"764_CR69","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1182\/blood-2021-147299","volume":"138","author":"RM Myers","year":"2021","unstructured":"Myers RM, Devine K, Li Y, Lawrence S, Leahy AB, Liu H, et al. Outcomes after reinfusion of CD19-specific chimeric antigen receptor (CAR)-modified T cells in children and young adults with relapsed\/refractory B-cell acute lymphoblastic leukemia. Blood. 2021;138(Supplement 1):474.","journal-title":"Blood"},{"issue":"18","key":"764_CR70","doi-asserted-by":"publisher","first-page":"4623","DOI":"10.3390\/cancers15184623","volume":"15","author":"NS Fracchiolla","year":"2023","unstructured":"Fracchiolla NS, Scium\u00e8 M, Papayannidis C, Vitale A, Chiaretti S, Annunziata M, et al. Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed\/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study. Cancers (Basel). 2023;15(18):4623.","journal-title":"Cancers (Basel)."},{"key":"764_CR71","doi-asserted-by":"crossref","unstructured":"Gibson A, Nunez C, Robusto L, Kammerer B, Garcia M, Roth M et al. Combination low-intensity chemotherapy plus inotuzumab ozogamicin, blinatumomab and rituximab for pediatric patients with relapsed\/refractory B-cell acute lymphoblastic leukemia. Haematologica (2024)1;109(9):3042\u20137.","DOI":"10.3324\/haematol.2023.284950"},{"key":"764_CR72","doi-asserted-by":"crossref","unstructured":"Shah BD, Cassaday RD, Park JH, Houot R, Oluwole OO, Logan AC, et al. P356: Subgroup analyses of kte-x19, an anti-cd19 chimeric\u2026 : HemaSphere. [cited 2025 Mar 2]; Available from: https:\/\/journals.lww.com\/hemasphere\/fulltext\/2022\/06003\/p356__subgroup_analyses_of_kte_x19,_an_anti_cd19.256.aspx.","DOI":"10.1097\/01.HS9.0000844312.20412.89"},{"issue":"9","key":"764_CR73","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1200\/JCO.21.01405","volume":"40","author":"RM Myers","year":"2022","unstructured":"Myers RM, Taraseviciute A, Steinberg SM, Lamble AJ, Sheppard J, Yates B, et al. Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL. JCO. 2022;40(9):932\u201344.","journal-title":"JCO"},{"issue":"3","key":"764_CR74","first-page":"596","volume":"110","author":"M Algeri","year":"2025","unstructured":"Algeri M, Massa M, Pagliara D, Bertaina V, Galaverna F, Pili I, et al. Outcomes of children and young adults with B-cell acute lymphoblastic leukemia given blinatumomab as last consolidation treatment before allogeneic hematopoietic stem cell transplantation. Haematologica. 2025;110(3):596\u2013607.","journal-title":"Haematologica"},{"issue":"16suppl","key":"764_CR75","doi-asserted-by":"publisher","first-page":"7000","DOI":"10.1200\/JCO.2023.41.16_suppl.7000","volume":"41","author":"C Roddie","year":"2023","unstructured":"Roddie C, Sandhu KS, Tholouli E, Shaughnessy P, Barba P, Guerreiro MN, et al. Safety and efficacy of obecabtagene autoleucel (obe-cel, AUTO1), a fast-off rate CD19 CAR, in relapsed\/refractory adult B-cell acute lymphoblastic leukemia (r\/r B-ALL): Top line results of the pivotal FELIX study. J Clin Oncol. 2023;41 Suppl 16:7000\u20137000.","journal-title":"JCO"},{"issue":"6","key":"764_CR76","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1038\/s41375-020-01056-6","volume":"35","author":"C Zhang","year":"2021","unstructured":"Zhang C, Wang XQ, Zhang RL, Liu F, Wang Y, Yan ZL, et al. Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant. Leukemia. 2021;35(6):1563\u201370.","journal-title":"Leukemia"},{"issue":"9","key":"764_CR77","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.clml.2020.04.007","volume":"20","author":"J Hua","year":"2020","unstructured":".Hua J, Zhang J, Wu X, Zhou L, Bao X, Han Y, et al. Allogeneic Donor-Derived Anti-CD19 CAR T Cell Is a Promising Therapy for Relapsed\/Refractory B-ALL After Allogeneic Hematopoietic Stem-Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2020;20(9):610\u20136.","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-025-00764-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-025-00764-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-025-00764-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T03:03:39Z","timestamp":1769051019000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-025-00764-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["764"],"URL":"https:\/\/doi.org\/10.1007\/s11899-025-00764-z","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"7 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The authors declare that they have no conflicts of interest relevant to this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"20"}}